ASP II (Ancrod Stroke Program) Study of Acute Viprinex for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke

Trial Profile

ASP II (Ancrod Stroke Program) Study of Acute Viprinex for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Ancrod (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms ASP-II
  • Most Recent Events

    • 14 Jan 2009 Following a detailed analysis of the recent interim results of this clinical trial, the company has decided not to develop Viprinex further for the treatment of acute ischemic stroke, as reported by Neurobiological Technologies in a media release.
    • 17 Dec 2008 Status changed is now discontinued, as reported by clinicaltrials.gov.
    • 17 Dec 2008 Status changed from recruiting to suspended. An analysis of trial data is expected in early 2009, results of which will determine whether further development of Ancrod will continue.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top